Home Page

Dr. Marcel Behr elected to Fellowship in the AAM

Dr. Marcel Behr has been elected to Fellowship in the American Academy of Microbiology. The Academy, the honorific leadership group within the American Society for Microbiology, recognizes excellence, originality, and leadership in the microbiological sciences, and his election to this group is a mark of distinction. Congratulations Dr. Behr!

Confronting a killer : New article about the McGill TB Centre written by Patrick McDonagh in McGill News 

THE INTERNATIONAL COMMUNITY IS TURNING ITS ATTENTION TO THE MENACE OF TB AND A RESEARCH CENTRE AT MCGILL IS ALREADY PLAYING A MAJOR ROLE.

Read more

McGill International TB Centre designated as a PAHO/WHO Collaborating Center for Tuberculosis Research

 about Paho/WHO CC

Message from the Director:

With over 10 million new TB cases, and 1.6 million deaths, TB is the leading infectious killer of humanity. In Canada, the TB rate among the Inuit is about 283 times higher than that of the Canadian-born non-Indigenous. Thankfully, the world has committed to end the TB epidemic by 2030, and the Canadian government has pledged to end the TB epidemic in the Inuit Nunangat by 2030. The McGill International TB Centre is a world leader in the interdisciplinary study of TB. This Centre brings together more than 20 investigators with expertise in biomedical, clinical, epidemiologic and social aspects of TB. We work to better understand TB pathogenesis and host resistance, and also develop and evaluate new diagnostics, vaccines and treatment regimens for the control of TB. By means of quality training, technical assistance, capacity building, and policy-relevant research, our Centre aims to make a positive contribution to ending the TB epidemic nationally as well as globally.

Madhukar Pai,

December 3rd, 2018

TB-oriented and other courses at the McGill Summer Institute in Infectious Diseases and Global Health

View website

 Recent Media Appearances

• Confronting a killer 
• Madhukar Pai at the Climbing Ladders event by TEDxMcGill 
• Percée canadienne aux répercussions mondiales dans le traitement contre la tuberculose
• Tuberculosis fight to get $13B USD a year
• Madhukar Pai at the UN General Assembly: High-level meeting on the fight against tuberculosis - Multi-stakeholder Panel 2
• Fight to End TB - SDG Media Zone at the 73rd session of United Nations General Assembly
• New study uncovers vast variation and significant deficits in tuberculosis care in urban India
• ‘Latent’ Tuberculosis? It’s Not That Common, Experts Find
• ​Click here for more

MARCH 22nd
TB CENTRE DAY

THE NEW ENGLAND JOURNAL OF MEDICINE: Watch video of Dr. Menzies talking about his studies

- Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults. Menzies D et al.N Engl J Med.August 2, 2018;379:440-453 Read article

- Safety and Side Effects of Rifampin versus Isoniazid in Children. Diallo T et al.N Engl J Med.August 2, 2018; 379:454-463 Read article

Read article featured in the Montreal Gazette

Read about the studies - MUHC Newsroom

- Treatment correlates of successful outcomes inpulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. Ahmad N et al.The Lancet. September 8, 2018;392(10150):821-834 Read article

Read about this study in the McGill Reporter

Maziar Divangahi and Nargis KhanBeyond Killing Tuberculosis

Historically, our view of host defense against infection was that we must eliminate pathogens to eradicate disease. However, this perspective has recently been challenged as scientists have taken a lesson from plant biologists about an ancient strategy involving the ability to “tolerate” rather than “resist” infection to maintain health. This concept, referred to as “disease tolerance”, provides an opportunity to develop new strategies that mitigate the consequences of infection. Read more

Mitochondrial cyclophilin D regulates T cell metabolic responses and disease tolerance to tuberculosis - Science Immunology

Eva Kaufman, August winner of the Relève étoile Jacques-Genest award and winner of an award from the German Society for Immunology 

Eva Kaufmann, a postdoctoral fellow in Medicine at McGill University, is the award winner of the Relève étoile Jacques-Genest award of the Fonds de recherche du Québec – Santé (FRQS).Her Award-winning publication: BCG Educates Hematopoietic Stem Cells to Generate Protective Innate Immunity against Tuberculosisis published in Cell. Congratulations Eva! More details on Relève étoile Jacques-Genest and on the German Society for Immunology award

Great job at knowledge synthesis by TB Centre researchers:

Nature Review Primer on TB.

Just got designated as a ‘Highly cited paper’ by the Web of Science, meaning it is among the top 1% of papers of similar age in the field of clinical medicine! Read it here: http://go.nature.com/2Da2w2q 

The top-cited systematic reviews/meta-analyses in tuberculosis research:

McGill authors topped the rankings as first and corresponding authors in systematic reviews and meta-analyses in TB research.

​The 100 top-cited tuberculosis research studies: 

​According to a study, McGill researchers account for 6% of the world's best cited TB papers which is very high ranking! The 100 top-cited tuberculosis research https://www.atsjournals.org/doi/10.1164/rccm.201707-1489PPstudies (International Union Against Tuberculosis and Lung Disease) Download

Positions in Tuberculosis Research Available:

• Postdoctoral Fellowship with Dr. Madhukar Pai

  ---

   

   

Selected Recent TB Articles/Publications

• Beyond Killing Mycobacterium tuberculosis: Disease Tolerance. Front Immunol.

• What is Next for the Standard Short-Course Regimen for Treatment of Multidrug-Resistant Tuberculosis. Am J Trop Med Hyg.

• New short regimens for latent tuberculosis treatment: safety first! Eur Respir J.

• Causal inference with multiple concurrent medications: A comparison of methods and an application in multidrug-resistant tuberculosis. Stat Methods Med Res

• Advances in the understanding of Mycobacterium tuberculosis transmission in HIV-endemic settings. Lancet Infect Dis

• Neutrophils: Innate Effectors of TB Resistance? Front Immunol

• Click here for entire year's publications

Our centre brings together over 20 investigators with expertise spanning epidemiology, policy setting, economic analyses, implementation research, meta-analyses,  qualitative research to basic science in microbiology, host genetics and immune response. 

The work is done both at an academic centre and with a number of collaborating groups around the world. On these pages, we introduce the faculty members who are members of our centre and describe our training programs for students.  Find out why our Centre is a world leader in the interdisciplinary study of TB and how we work together to unravel the many mysteries of this recalcitrant disease.